|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Florida Biologix Announces Manufacturing Agreement with NanoSonic Products, Inc. to Formulate, Fill and Finish Trappsol Cyclo
2/28/2012 8:11:13 AM
ALACHUA, Fla.--(BUSINESS WIRE)--NanoSonic Products, Inc., a wholly owned subsidiary of CTD Holdings, Inc. (OTCQB:CTDH), and Florida Biologix have signed a contract for the formulation and fill of the sterile liquid form of its Trappsol Cyclo product, an FDA and EMEA designated orphan drug for the treatment of Niemann Pick Type-C disease, also known as Childhood Alzheimer's, which affects children and adults and manifests with progressive neurological symptoms. Trappsol Cyclo is currently being administered in the U.S. under a compassionate use IND.
|
|
|
|
|
|
|
|
|
|
|